WO2015040422A1 - Composition for the oral delivery of compounds - Google Patents

Composition for the oral delivery of compounds Download PDF

Info

Publication number
WO2015040422A1
WO2015040422A1 PCT/GB2014/052870 GB2014052870W WO2015040422A1 WO 2015040422 A1 WO2015040422 A1 WO 2015040422A1 GB 2014052870 W GB2014052870 W GB 2014052870W WO 2015040422 A1 WO2015040422 A1 WO 2015040422A1
Authority
WO
WIPO (PCT)
Prior art keywords
component
composition
water
tablet
pill
Prior art date
Application number
PCT/GB2014/052870
Other languages
French (fr)
Inventor
Howard Buckley
Original Assignee
Howard Buckley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Howard Buckley filed Critical Howard Buckley
Publication of WO2015040422A1 publication Critical patent/WO2015040422A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds

Definitions

  • the present invention relates to compositions for the oral delivery of compounds.
  • Oral delivery of compositions is a preferable route of delivery due to the ease of administration, user compliance and flexibility in formulation etc.
  • many users are unwilling or less inclined to take oral compositions due to issues with palatability, or because they have to take separate doses of different compounds.
  • a first aspect provides a composition for the oral delivery of compounds, the composition comprising:
  • At least a first component formed as a generally insoluble pill or tablet, and at least a second component provided as a soluble layer or coating on the pill or tablet;
  • composition arranged so that upon addition to water, the soluble layer or coating dissolves leaving one or more generally insoluble pills or tablets.
  • the average density of the first component may be less than 1 g/cm 3 so that the first component floats in water.
  • the average density of the first component may be less than or equal to 1 g/cm 3 so that the first component is suspended in water or in a solution.
  • the second component may effervesce upon addition to water.
  • effervescing speeds up the time it takes for the soluble second component to dissolve in water, decreasing the waiting time for a user before they can consume the composition.
  • the effervescence serves as a visual indicator to the user that the composition is dissolving in the water.
  • a second aspect provides a composition for the oral delivery of compounds, the composition comprising:
  • At least a first component formed as a generally insoluble pill or tablet, with an average density less than or equal to 1 g/cm 3 so that the first component floats or is suspended in water, and
  • At least a second component provided as a soluble layer or coating on the pill or tablet;
  • composition arranged so that upon addition to water, the soluble layer or coating dissolves and effervesces, leaving one or more generally insoluble pills or tablets.
  • the first component may comprise gases to lower the average density of the first component.
  • the second component may comprise an acid and an alkali, for example citric acid and sodium bicarbonate, so that it effervesces.
  • the composition may have a generally less palatable compound provided in the pill or tablet of the first component.
  • the less palatable compound may have a strange taste.
  • the less palatable compound may comprise vitamins which are not palatable in their more refined form or which may have a strange or unpleasant odour.
  • the pill or tablet may be coated or formed to inhibit flavouring of the water by the less palatable component.
  • the generally insoluble component may have a substantially impermeable outer layer.
  • the second component may be arranged to dissolve rapidly.
  • the composition may be arranged to substantially dissolve to reveal the pill or tablet of the first component within 30 seconds in water at a temperature of between 5 and 25 degrees centigrade.
  • the first component may be encapsulated by the second component.
  • the second component may substantially surround the pill or tablet of the first component.
  • the pill or tablet of the first component may have at least external colouring of a first colour
  • the second component may have at least external colouring of a second colour.
  • the colouring of the second component may colour water when the second component dissolves in water.
  • the second component may further comprise flavourings.
  • such a composition facilitates the oral delivery of a less palatable compound with a more palatable compound.
  • the flavourings or colourings of the soluble second component may increase the appeal (both in terms of visual appeal and taste appeal) of the composition to the user.
  • a user can then drink the water comprising the dissolved soluble second component and, whilst drinking the water, simultaneously swallow the generally insoluble first component, which may be more unpalatable or bitter.
  • such a composition allows a plurality of compounds to be contained within a single composition or dose.
  • the first component may comprise at least one active ingredient selected from the list of:
  • the second component may comprise at least one ingredient selected from the list of: amino acids,
  • flavourings
  • the pill or tablet of the first component may have a different shape to that of the composition.
  • the pill or tablet may have a different shape to that of the first component.
  • the pill or tablet may be spherical, cylindrical, cube, cuboid, star-shaped or any other shape.
  • the first component may have at least two pills or tablets.
  • Fig. 1 shows a cross-section through an example composition
  • Fig. 2 shows a cross-section through another example composition
  • Fig. 3 shows a perspective view of the composition of Fig. 1 in use in a glass of water
  • Fig. 4 shows a perspective view of the composition of Fig. 2 in use in a glass of water.
  • Fig. 1 shows an example composition 1.
  • Composition 1 is in the form of a tablet.
  • the composition 1 comprises a generally insoluble first component 3 in the form of a generally cuboid tablet and a soluble second component 5 also in the form of a generally cuboid tablet.
  • the generally insoluble component 3 is coupled to a surface of the soluble second component 5.
  • Both the generally insoluble component 3 and the soluble second component 5 are brightly coloured, with the generally insoluble component 3 having a contrasting colour to the soluble component 5.
  • the composition 1 may comprise a carrier component.
  • the carrier component may be between the soluble second component 5 and the generally insoluble first component 3, so that the carrier component couples or binds the soluble second component 5 and the generally insoluble first component 3 together.
  • composition 10 is in the form of a tablet.
  • the composition 10 comprises a generally insoluble first component 13 in the form of a star-shaped pill, and a soluble second component 1 1 in the form of a generally cuboid tablet.
  • the generally insoluble component 13 is encapsulated by the soluble second component 1 1 , so that the soluble second component substantially surrounds the pill of the generally insoluble first component 13.
  • Both the generally insoluble component 13 and the soluble second component 1 1 are brightly coloured, with the generally insoluble component 13 having a contrasting colour to the soluble component 1 1.
  • the generally insoluble first component 3, 13 has an overall density less than 1 g/cm 3
  • the generally insoluble first component 3, 13 comprises a filler component comprising gases or other comestible fillers with a density less than 1 g/cm 3 , and at least one of amino acids, vitamins, botanical or herbal extracts, medicinal compounds or drugs, and mineral salts, with a density that may be greater than 1 g/cm 3 .
  • the filler component decreases the average density of the generally insoluble first component 3, 13 so that denser (i.e. greater than 1 g/cm 3 ) ingredients may be used but the generally insoluble first component 3, 13 still floats.
  • the generally insoluble component 3, 13 may have a generally unpalatable, such as a bitter, sour or acidic, or highly salty taste.
  • a generally unpalatable such as a bitter, sour or acidic, or highly salty taste.
  • individual tastes may differ, it is well known that certain compounds, ingredients or medicaments are not well-liked and of course taste tests may be conducted.
  • the example embodiments described here allow it to be mitigated.
  • bitterness can be perceived differently by different users, it is generally accepted that there is a threshold for perceiving a bitter taste. This threshold is defined relative to the concentration of quinine in water, and averages at around 0.000008 M. For example, quinine gives tonic water its bitter taste.
  • vitamins in their more refined form may have a strange or unpalatable taste and/or odour.
  • the less palatable first component 3, 13 may comprise B vitamins.
  • the soluble second component 5, 1 1 has an active ingredient including at least one of amino acids, vitamins, botanical or herbal extracts, medicinal compounds or drugs, and mineral salts.
  • the active compound of the soluble second component 5, 1 1 is water soluble.
  • the soluble second component 5, 1 1 is soluble in water and is effervescent, releasing carbon dioxide in water, so that the soluble second component 5, 1 1 appears to "fizz".
  • the effervescence not only serves as a visual indicator to the user that the composition is working, but also speeds up the rate of dissolution of the soluble second component 5, 1 1.
  • the soluble second component 5, 1 1 is a fast-release component because the active compound in the soluble second component 5, 1 1 dissolves into the water as the soluble second component 5, 1 1 dissolves.
  • the soluble second component 5, 1 1 may comprise an acid source and an alkaline source.
  • the alkaline source may comprise carbonate or bicarbonate such as sodium bicarbonate, potassium or calcium (bi) carbonate, or sodium glycine carbonate.
  • the acid source may comprise citric acid in both hydrated and/or anhydrous forms, or may comprise other edible acids such as tartaric acid, fumaric acid, adipic acid and malic acid.
  • the carbonate, which represents the source of carbon dioxide, is a generally water soluble alkaline carbonate.
  • the soluble second component 5, 1 1 may also comprise a lubricant which may be selected from water soluble compounds to form a clear solution.
  • the lubricant may comprise sodium benzoate, sodium acetate, fumaric acid, polyethylene glycols (PEG) higher than 4000, alanine and glycine.
  • Conventional excipients such as diluents, ligands, buffering agents, sweeteners, flavourings, colourings, solubilizers, disintegrants, wetting agents and other excipients of common use may also be added to the soluble second component 5, 1 1.
  • the generally insoluble first component 3, 13 is not as soluble in water as the soluble second component 5, 1 1 , and floats in water.
  • the generally insoluble first component 3, 13 has a substantially impermeable outer layer to reduce the solubility of the component. This helps to prevent any unpalatable taste of the generally insoluble first component 3, 13 from leaching into and flavouring the water.
  • Fig. 3 shows the composition of Fig. 1 placed into a glass 7 of water 9. It can be seen that the soluble second component 5 sinks to the bottom of the glass 7, and releases bubbles of carbon dioxide gas. The soluble second component 5 also releases palatable flavourings and colourings that are appealing to a user.
  • the generally insoluble first component 3, on the other hand, has separated from the soluble second component 5, and remains as a residual mass in the form of a cuboid tablet, floating on the surface of the water 9.
  • Fig. 4 shows the composition of Fig. 2 placed into a glass 17 of water 19. It can be seen that the soluble second component 1 1 sinks to the bottom of the glass 17, and releases bubbles of carbon dioxide gas. The soluble second component 1 1 also releases palatable flavourings and colourings that are appealing to a user. As the soluble second component 11 dissolved, the generally insoluble first component 13 is revealed within the soluble second component 1 1 and floats to the surface of the water 19 in the form of a star-shaped pill.
  • a user can then drink the glass 7, 17 comprising the dissolved soluble second component 5, 1 1 and the generally insoluble first component 3, 13.
  • the water 9, 19 has been coloured and flavoured by the soluble second component 5, 1 1 , making the water appealing to drink (both in terms of taste and visual appeal).
  • the appealing nature of the water 9, 19 therefore means a user can drink the water and swallow the bitter tasting generally insoluble first component 3, 13 without having to taste the bitter tasting generally insoluble first component 3, 13.
  • the dissolved soluble second component 5, 1 1 allows for the fast-release of ingredients and compounds comprised in the soluble second component 5, 1 1 , whereas the generally insoluble first component 3, 13 allows the release of potentially unpalatable ingredients and compounds within the stomach.
  • the generally insoluble first component 3, 13 may comprise at least two pills or tablets.
  • the generally insoluble first component 3, 13 may comprise a pill and a tablet, or two pills and two tablets.
  • the pills and/or tablets may comprise different ingredients, may be of a different shape or colour and may have a different flavour.
  • a pill or tablet has a known meaning in the art, and may be configured for the oral delivery of compounds.
  • the pill or tablet is sufficiently large such that it comprises a sufficient quantity of the compounds for a dose, but sufficiently small such that it can be swallowed.
  • the pill and/or tablet may comprise a small, rounded mass designed for oral consumption, for example by swallowing whole or chewing.
  • the pill and/or tablet may comprise a compressed solid substance comprising a measured amount of an active ingredient, for example a medicine or drug. The measured amount or dose may be a measured amount or dose for an adult.
  • the overall or average density of the composition may be less than or equal to 1 g/cm 3 so that the composition floats or is suspended in water or a solution. In some configurations, the average density of the first component is less than or equal to 1 g/cm 3 so that the first component floats or is suspended in water or solution.
  • the composition is configured to be added to solutions other than water, for example to fruit juices or sparkling beverages.
  • the overall or average density of the composition, or the average density of the first component is the same as the average density of the solution within which the composition is configured to be added to.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

A composition for the oral delivery of compounds is described herein. The composition comprises at least a first component formed as a generally insoluble pill or tablet, and at least a second component provided as a soluble layer or coating on the pill or tablet. The composition is arranged so that upon addition to water, the soluble layer or coating dissolves leaving one or more generally insoluble pills or tablets.

Description

COMPOSITION FOR THE ORAL DELIVERY OF COMPOUNDS Field of the invention
The present invention relates to compositions for the oral delivery of compounds.
Background
Oral delivery of compositions is a preferable route of delivery due to the ease of administration, user compliance and flexibility in formulation etc. However, many users are unwilling or less inclined to take oral compositions due to issues with palatability, or because they have to take separate doses of different compounds.
A need therefore exists to improve the delivery of oral compositions, particularly oral compositions comprising an unpalatable compound.
Summary of invention
Accordingly, a first aspect provides a composition for the oral delivery of compounds, the composition comprising:
at least a first component formed as a generally insoluble pill or tablet, and at least a second component provided as a soluble layer or coating on the pill or tablet;
the composition arranged so that upon addition to water, the soluble layer or coating dissolves leaving one or more generally insoluble pills or tablets.
The average density of the first component may be less than 1 g/cm3 so that the first component floats in water. The average density of the first component may be less than or equal to 1 g/cm3 so that the first component is suspended in water or in a solution. The second component may effervesce upon addition to water. Advantageously, effervescing speeds up the time it takes for the soluble second component to dissolve in water, decreasing the waiting time for a user before they can consume the composition. In addition, the effervescence serves as a visual indicator to the user that the composition is dissolving in the water.
A second aspect provides a composition for the oral delivery of compounds, the composition comprising:
at least a first component formed as a generally insoluble pill or tablet, with an average density less than or equal to 1 g/cm3 so that the first component floats or is suspended in water, and
at least a second component provided as a soluble layer or coating on the pill or tablet;
the composition arranged so that upon addition to water, the soluble layer or coating dissolves and effervesces, leaving one or more generally insoluble pills or tablets.
The first component may comprise gases to lower the average density of the first component. The second component may comprise an acid and an alkali, for example citric acid and sodium bicarbonate, so that it effervesces.
The composition may have a generally less palatable compound provided in the pill or tablet of the first component. The less palatable compound may have a strange taste. For example, the less palatable compound may comprise vitamins which are not palatable in their more refined form or which may have a strange or unpleasant odour.
The pill or tablet may be coated or formed to inhibit flavouring of the water by the less palatable component. For example, the generally insoluble component may have a substantially impermeable outer layer.
The second component may be arranged to dissolve rapidly. For example, the composition may be arranged to substantially dissolve to reveal the pill or tablet of the first component within 30 seconds in water at a temperature of between 5 and 25 degrees centigrade.
The first component may be encapsulated by the second component. For example, the second component may substantially surround the pill or tablet of the first component. The pill or tablet of the first component may have at least external colouring of a first colour, and the second component may have at least external colouring of a second colour. The colouring of the second component may colour water when the second component dissolves in water. The second component may further comprise flavourings.
Advantageously, such a composition facilitates the oral delivery of a less palatable compound with a more palatable compound. For example, the flavourings or colourings of the soluble second component may increase the appeal (both in terms of visual appeal and taste appeal) of the composition to the user. A user can then drink the water comprising the dissolved soluble second component and, whilst drinking the water, simultaneously swallow the generally insoluble first component, which may be more unpalatable or bitter. Furthermore, such a composition allows a plurality of compounds to be contained within a single composition or dose.
For example, the first component may comprise at least one active ingredient selected from the list of:
amino acids,
vitamins,
botanical or herbal extracts,
medicinal compounds or drugs, and
mineral salts. The second component may comprise at least one ingredient selected from the list of: amino acids,
vitamins,
botanical or herbal extracts,
medicinal compounds or drugs
mineral salts, and
flavourings
The pill or tablet of the first component may have a different shape to that of the composition. For example, the pill or tablet may have a different shape to that of the first component. For example, the pill or tablet may be spherical, cylindrical, cube, cuboid, star-shaped or any other shape. The first component may have at least two pills or tablets.
Drawings
Embodiments of the disclosure will now be described, by way of example only, with reference to the accompanying drawings, in which:
Fig. 1 shows a cross-section through an example composition;
Fig. 2 shows a cross-section through another example composition;
Fig. 3 shows a perspective view of the composition of Fig. 1 in use in a glass of water;
Fig. 4 shows a perspective view of the composition of Fig. 2 in use in a glass of water.
Detailed description
Fig. 1 shows an example composition 1. Composition 1 is in the form of a tablet. The composition 1 comprises a generally insoluble first component 3 in the form of a generally cuboid tablet and a soluble second component 5 also in the form of a generally cuboid tablet. The generally insoluble component 3 is coupled to a surface of the soluble second component 5. Both the generally insoluble component 3 and the soluble second component 5 are brightly coloured, with the generally insoluble component 3 having a contrasting colour to the soluble component 5. In some configurations, the composition 1 may comprise a carrier component. The carrier component may be between the soluble second component 5 and the generally insoluble first component 3, so that the carrier component couples or binds the soluble second component 5 and the generally insoluble first component 3 together. Fig. 2 shows another example composition 10. Composition 10 is in the form of a tablet. In this example, the composition 10 comprises a generally insoluble first component 13 in the form of a star-shaped pill, and a soluble second component 1 1 in the form of a generally cuboid tablet. The generally insoluble component 13 is encapsulated by the soluble second component 1 1 , so that the soluble second component substantially surrounds the pill of the generally insoluble first component 13. Both the generally insoluble component 13 and the soluble second component 1 1 are brightly coloured, with the generally insoluble component 13 having a contrasting colour to the soluble component 1 1.
In both examples, the generally insoluble first component 3, 13 has an overall density less than 1 g/cm3 The generally insoluble first component 3, 13 comprises a filler component comprising gases or other comestible fillers with a density less than 1 g/cm3, and at least one of amino acids, vitamins, botanical or herbal extracts, medicinal compounds or drugs, and mineral salts, with a density that may be greater than 1 g/cm3. The filler component decreases the average density of the generally insoluble first component 3, 13 so that denser (i.e. greater than 1 g/cm3) ingredients may be used but the generally insoluble first component 3, 13 still floats.
In these examples, the generally insoluble component 3, 13 may have a generally unpalatable, such as a bitter, sour or acidic, or highly salty taste. Although individual tastes may differ, it is well known that certain compounds, ingredients or medicaments are not well-liked and of course taste tests may be conducted. Whatever the flavour, the example embodiments described here allow it to be mitigated. For example, although bitterness can be perceived differently by different users, it is generally accepted that there is a threshold for perceiving a bitter taste. This threshold is defined relative to the concentration of quinine in water, and averages at around 0.000008 M. For example, quinine gives tonic water its bitter taste. It is also known that vitamins in their more refined form may have a strange or unpalatable taste and/or odour. For example, the less palatable first component 3, 13 may comprise B vitamins.
The soluble second component 5, 1 1 has an active ingredient including at least one of amino acids, vitamins, botanical or herbal extracts, medicinal compounds or drugs, and mineral salts. The active compound of the soluble second component 5, 1 1 is water soluble.
The soluble second component 5, 1 1 is soluble in water and is effervescent, releasing carbon dioxide in water, so that the soluble second component 5, 1 1 appears to "fizz". The effervescence not only serves as a visual indicator to the user that the composition is working, but also speeds up the rate of dissolution of the soluble second component 5, 1 1. The soluble second component 5, 1 1 is a fast-release component because the active compound in the soluble second component 5, 1 1 dissolves into the water as the soluble second component 5, 1 1 dissolves.
In order to effervesce, the soluble second component 5, 1 1 may comprise an acid source and an alkaline source. For example the alkaline source may comprise carbonate or bicarbonate such as sodium bicarbonate, potassium or calcium (bi) carbonate, or sodium glycine carbonate. The acid source may comprise citric acid in both hydrated and/or anhydrous forms, or may comprise other edible acids such as tartaric acid, fumaric acid, adipic acid and malic acid. The carbonate, which represents the source of carbon dioxide, is a generally water soluble alkaline carbonate. The soluble second component 5, 1 1 may also comprise a lubricant which may be selected from water soluble compounds to form a clear solution. For example the lubricant may comprise sodium benzoate, sodium acetate, fumaric acid, polyethylene glycols (PEG) higher than 4000, alanine and glycine. Conventional excipients such as diluents, ligands, buffering agents, sweeteners, flavourings, colourings, solubilizers, disintegrants, wetting agents and other excipients of common use may also be added to the soluble second component 5, 1 1.
The generally insoluble first component 3, 13 is not as soluble in water as the soluble second component 5, 1 1 , and floats in water. The generally insoluble first component 3, 13 has a substantially impermeable outer layer to reduce the solubility of the component. This helps to prevent any unpalatable taste of the generally insoluble first component 3, 13 from leaching into and flavouring the water.
Fig. 3 shows the composition of Fig. 1 placed into a glass 7 of water 9. It can be seen that the soluble second component 5 sinks to the bottom of the glass 7, and releases bubbles of carbon dioxide gas. The soluble second component 5 also releases palatable flavourings and colourings that are appealing to a user. The generally insoluble first component 3, on the other hand, has separated from the soluble second component 5, and remains as a residual mass in the form of a cuboid tablet, floating on the surface of the water 9.
Fig. 4 shows the composition of Fig. 2 placed into a glass 17 of water 19. It can be seen that the soluble second component 1 1 sinks to the bottom of the glass 17, and releases bubbles of carbon dioxide gas. The soluble second component 1 1 also releases palatable flavourings and colourings that are appealing to a user. As the soluble second component 11 dissolved, the generally insoluble first component 13 is revealed within the soluble second component 1 1 and floats to the surface of the water 19 in the form of a star-shaped pill.
A user can then drink the glass 7, 17 comprising the dissolved soluble second component 5, 1 1 and the generally insoluble first component 3, 13. The water 9, 19 has been coloured and flavoured by the soluble second component 5, 1 1 , making the water appealing to drink (both in terms of taste and visual appeal). The appealing nature of the water 9, 19 therefore means a user can drink the water and swallow the bitter tasting generally insoluble first component 3, 13 without having to taste the bitter tasting generally insoluble first component 3, 13. When swallowed, the dissolved soluble second component 5, 1 1 allows for the fast-release of ingredients and compounds comprised in the soluble second component 5, 1 1 , whereas the generally insoluble first component 3, 13 allows the release of potentially unpalatable ingredients and compounds within the stomach.
It will be understood that in the above examples, other water-based liquids may be used. For example juice drinks may be used.
In some configurations, the generally insoluble first component 3, 13 may comprise at least two pills or tablets. For example, the generally insoluble first component 3, 13 may comprise a pill and a tablet, or two pills and two tablets. The pills and/or tablets may comprise different ingredients, may be of a different shape or colour and may have a different flavour.
A pill or tablet has a known meaning in the art, and may be configured for the oral delivery of compounds. As such, the pill or tablet is sufficiently large such that it comprises a sufficient quantity of the compounds for a dose, but sufficiently small such that it can be swallowed. The pill and/or tablet may comprise a small, rounded mass designed for oral consumption, for example by swallowing whole or chewing. The pill and/or tablet may comprise a compressed solid substance comprising a measured amount of an active ingredient, for example a medicine or drug. The measured amount or dose may be a measured amount or dose for an adult.
In some configurations, the overall or average density of the composition may be less than or equal to 1 g/cm3 so that the composition floats or is suspended in water or a solution. In some configurations, the average density of the first component is less than or equal to 1 g/cm3 so that the first component floats or is suspended in water or solution.
In some configurations, the composition is configured to be added to solutions other than water, for example to fruit juices or sparkling beverages. In some configurations the overall or average density of the composition, or the average density of the first component, is the same as the average density of the solution within which the composition is configured to be added to.
Other examples and variations will be apparent to the skilled reader in the context of the present disclosure.

Claims

CLAIMS:
1. A composition for the oral delivery of compounds, the composition comprising: at least a first component formed as a generally insoluble pill or tablet, and at least a second component provided as a soluble layer or coating on the pill or tablet;
the composition arranged so that upon addition to water, the soluble layer or coating dissolves leaving one or more generally insoluble pills or tablets.
2. The composition of claim 1 wherein the average density of the first component is less than or equal to 1 g/cm3 so that the first component floats or is suspended in water.
3. The composition of claim 1 or 2 wherein the second component effervesces upon addition to water.
4. A composition for the oral delivery of compounds, the composition comprising: at least a first component formed as a generally insoluble pill or tablet, with an average density less than or equal to 1 g/cm3 so that the first component floats or is suspended in water, and
at least a second component provided as a soluble layer or coating on the pill or tablet;
the composition arranged so that upon addition to water, the soluble layer or coating dissolves and effervesces, leaving one or more generally insoluble pills or tablets.
5. The composition of any one of the previous claims wherein a generally less palatable compound is provided in the pill or tablet of the first component.
6. The composition of claim 5 wherein the pill or tablet is coated or formed to inhibit flavouring of the water by the less palatable compound.
7. The composition of any one of the previous claims wherein the second component is arranged to dissolve rapidly.
8. The composition of any one of the previous claims wherein the first component is encapsulated by the second component.
5 9. The composition of any one of the previous claims wherein the second component substantially surrounds the pill or tablet of the first component.
10. The composition of any one of the previous claims wherein the pill or tablet of the first component has at least external colouring of a first colour, and the second
10 component has at least external colouring of a second colour.
1 1. The composition of claim 10 wherein the colouring of the second component colours water when the second component dissolves in water.
15 12. The composition of any one of the previous claims wherein the first component comprises at least one active ingredient selected from the list of:
amino acids,
vitamins,
botanical or herbal extracts,
20 medicinal compounds or drugs, and
mineral salts.
13. The composition of any one of the previous claims wherein the second component comprises at least one ingredient selected from the list of:
25 amino acids,
vitamins,
botanical or herbal extracts,
medicinal compounds or drugs
mineral salts, and
30 flavourings
14. The composition of any one of the previous claims wherein the pill or tablet of the first component has a different shape to that of the composition.
15. The composition of any one of the previous claims wherein the first component has at least two pills or tablets.
16. A composition substantially as described herein, with reference to the accompanying drawings.
PCT/GB2014/052870 2013-09-23 2014-09-22 Composition for the oral delivery of compounds WO2015040422A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB201316857A GB201316857D0 (en) 2013-09-23 2013-09-23 Composition for the oral delivery of compounds
GB1316857.0 2013-09-23
GB201407847A GB2518475A (en) 2013-09-23 2014-05-02 Composition for the oral delivery of compounds
GB1407847.1 2014-05-02

Publications (1)

Publication Number Publication Date
WO2015040422A1 true WO2015040422A1 (en) 2015-03-26

Family

ID=49553259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2014/052870 WO2015040422A1 (en) 2013-09-23 2014-09-22 Composition for the oral delivery of compounds

Country Status (2)

Country Link
GB (2) GB201316857D0 (en)
WO (1) WO2015040422A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10857092B2 (en) 2019-03-14 2020-12-08 Glen D Lindbo Avoiding gag reflex to enable swallowing pills

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2230185A (en) * 1989-04-12 1990-10-17 Warner Lambert Co Differential release layered pharmaceutical tablet
WO1996033700A1 (en) * 1995-04-28 1996-10-31 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
EP0875245A2 (en) * 1997-04-28 1998-11-04 Hercules Incorporated Substained release polymer blend matrix for pharmaceutical application
WO2003101431A1 (en) * 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
WO2007132296A2 (en) * 2005-12-30 2007-11-22 Intelgenx Corp. Multilayer tablet
WO2013001516A1 (en) * 2011-06-29 2013-01-03 Ranbaxy Laboratories Limited Multilayered dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE164514T1 (en) * 1992-08-06 1998-04-15 Gergely Gerhard EASY TO TAKE EFFORTABLE TABLET
DE19931667A1 (en) * 1999-07-08 2001-01-11 Basf Ag Flexible, water-soluble or water-dispersible coating agent, binder or film former for pharmaceutical formulations, comprises new or known vinyl ester-polyether graft copolymer,
FR2787715B1 (en) * 1998-12-23 2002-05-10 Synthelabo PHARMACEUTICAL COMPOSITION COMPRISING A HYPNOTIC COMPOUND OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS
DE10207427A1 (en) * 2002-02-21 2003-09-04 Basf Ag Rapidly soluble film coating based on polyvinyl alcohol-polyether graft copolymers in combination with components containing hydroxyl, amide or ester functions
CN1688292A (en) * 2002-09-04 2005-10-26 兰贝克赛实验室有限公司 Taste masked dosage forms and processes for their preparation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2230185A (en) * 1989-04-12 1990-10-17 Warner Lambert Co Differential release layered pharmaceutical tablet
WO1996033700A1 (en) * 1995-04-28 1996-10-31 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
EP0875245A2 (en) * 1997-04-28 1998-11-04 Hercules Incorporated Substained release polymer blend matrix for pharmaceutical application
WO2003101431A1 (en) * 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
WO2007132296A2 (en) * 2005-12-30 2007-11-22 Intelgenx Corp. Multilayer tablet
WO2013001516A1 (en) * 2011-06-29 2013-01-03 Ranbaxy Laboratories Limited Multilayered dosage form

Also Published As

Publication number Publication date
GB201316857D0 (en) 2013-11-06
GB201407847D0 (en) 2014-06-18
GB2518475A (en) 2015-03-25

Similar Documents

Publication Publication Date Title
US6589555B2 (en) Effervescent vitaceutical compositions and related methods
US5766622A (en) Inhibiting undesirable taste in oral compositions
ES2210378T3 (en) NEUTRALIZATION OF ACID FOODS AND ACID-BASED MEDICATIONS.
US20070059362A1 (en) Effervescent rehydrating beverage tablet/granules
ES2831412T3 (en) Compositions comprising PEG and ascorbate
US10617714B2 (en) Effervescent dosage form
ES2472297T3 (en) Beverage based on granular gelatin for medication and process to produce it
ES2886335T3 (en) Improvements made in or associated with colon cleansing compositions
US10322144B2 (en) Effervescent dosage form
ES2405531B1 (en) Solid formulations and their use in the maintenance of gastrointestinal health   
US6399661B1 (en) Oral creatine supplement and method for making same
JP2008072969A (en) Combination confectionery of tablet confectionery and candy, and method for producing the same
KR20170083508A (en) Jelly containing free amino acid or salt thereof
WO2015040422A1 (en) Composition for the oral delivery of compounds
US20190083366A1 (en) Mouthwash granules for an aqueous solution
US10857092B2 (en) Avoiding gag reflex to enable swallowing pills
WO2002000043A1 (en) A nutrient beverage
US20210046004A1 (en) Effervescent powder delivery system
AU2007229424A1 (en) Drinking straw for delivering an oral ingestant
IT201900015192A1 (en) Edible formulations based on active ingredients and arginine
AU5409701A (en) Nutrient beverage
KR20160130488A (en) Method of cleansing the colon
AU2001268817A1 (en) A nutrient beverage
MXPA99001598A (en) Inhibiting undesirable taste in oral compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14789343

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14789343

Country of ref document: EP

Kind code of ref document: A1